Home » Johnson Controls Secures Global Facilities Management Win With GlaxoSmithKline
Johnson Controls Secures Global Facilities Management Win With GlaxoSmithKline
PharmaManufacturing.com
05/11/2010
Johnson Controls Global WorkPlace Solutions today announced it has won a global contract to provide workplace services to pharmaceutical and healthcare company GlaxoSmithKline (GSK).
The five-year contract builds on an 18-year relationship Johnson Controls has had with GSK as a facility services provider. It will initially cover GSK sites across North and South America, Europe and China – with other sites being brought on in a managed process as they are ready. Johnson Controls will provide GSK with workplace services including technical and engineering services, energy management, project management and pharmaceutical services, for the company's research and development, manufacturing and corporate offices.
With headquarters in the United Kingdom and with operations based around the world, GSK is a market leader in the pharmaceutical and healthcare industry. Through this contract Johnson Controls is helping GSK achieve its strategic priority of "simplifying the operating model" by delivering services that are responsive to changes in GSK's business model.
Guy Holden, vice president & general manager, Global WorkPlace Solutions, said, "Johnson Controls has had the privilege of providing GSK with facilities services for the last 18 years. This major new contract win represents an exciting expansion of our relationship and the opportunity to deliver workplace services that make a direct and meaningful contribution to GSK's business.
"One of the main reasons we were selected was because of our proven track record in the pharmaceutical and healthcare industry internationally, and in delivering transformational change in highly regulated life science environments," Holden added.
John Summers, vice president and general manager of Life Sciences, Global WorkPlace Solutions commented: "We are extremely pleased to be partnering with GSK to deliver workplace services for the company globally.
"The contract creates further expansion of our footprint in the United Kingdom and in the United States and expands our current operations in emerging markets such as Brazil and China. As GSK continues to develop the global services model into other business units and geographies our opportunities for continued growth are significant," Summers added.
Johnson Controls Global WorkPlace Solutions will start delivering services under the new contract beginning in summer 2010.
Johnson Controls Global WorkPlace Solutions is the world's largest global real estate and facilities management business offering a single-source for real estate portfolio management, design and project management, integrated technologies, strategic consulting, and energy and facilities management services. The business unit has more than 17,000 employees working with clients across 75 countries, serving real estate portfolios and managing facilities totaling approximately 1.5 billion square feet.
About Johnson Controls
Johnson Controls is a global diversified technology and industrial leader serving customers in over 150 countries. Our 130,000 employees create quality products, services and solutions to optimize energy and operational efficiencies of buildings; lead-acid automotive batteries and advanced batteries for hybrid and electric vehicles; and interior systems for automobiles. Our commitment to sustainability dates back to our roots in 1885, with the invention of the first electric room thermostat. Through our growth strategies and by increasing market share we are committed to delivering value to shareholders and making our customers successful.
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers

Print page